Integrin αvβ8 Antibodies Block TGF-β Activation
Find Innovative SolutionsGenerate Solutions
Solution Overview
Problem
Current therapies lack effective methods to specifically target and inhibit the activation of TGF-β by integrin αvβ8, which is crucial for regulating immune responses and is implicated in various diseases including cancer and viral infections.
Innovation Solution
Development of antibodies that specifically bind to integrin αvβ8, such as HuC6D4F12, which have improved affinity and specificity, blocking the activation of TGF-β and inhibiting its function, thereby modulating immune responses.
Engineering Contradictions & Design Principles
Engineering Contradiction Analysis
1Reliability
If antibodies with improved affinity and specificity for integrin αvβ8 are developed, then the ability to block TGF-β activation is enhanced, but the complexity of antibody development and characterization increases
Solution Approach 1:
The patent applies parameter changes by modifying amino acid sequences in the antibody variable regions (specifically CDRs) to optimize binding affinity and specificity for integrin αvβ8. This involves systematic variation of sequence parameters to achieve improved functional outcomes while managing development complexity through rational design approaches.
2Reliability
If current therapies are used without specific αvβ8 targeting, then treatment simplicity is maintained, but effectiveness in regulating immune responses and treating diseases is insufficient
Solution Approach 1:
The patent introduces specific antibodies as intermediary molecules that mediate the interaction between therapeutic agents and integrin αvβ8. These antibodies serve as targeted delivery vehicles or blocking agents, enhancing therapeutic effectiveness by specifically interfering with the αvβ8-mediated TGF-β activation pathway while maintaining manageable therapy complexity through standardized antibody platforms.
Data Source
AI summary
Antibodies that bind to αvβ8 are provided.